Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Jan 12,2016
Energy Sensor As Potential Target For Future Cancer Drugs
    An energy sensing enzyme can potentially become a therapeutic target for future cancer drugs as it is responsible for sensing the available supply of GTP — an energy source that fuels the uncontrolled growth of cancer cells, new research has found. An international study team formed by a University of Cincinnati (UC) cancer researcher foundRead more
More
Energy Sensor As Potential Target For Future Cancer Drugs
Jan 12,2016
Lab Generated, Insulin Producing Cells Prevent Onset of Diabetes
    Personalized medicine has recently taken a step forward for patients suffering from diabetes. In a new study, scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully functional pancreatic cells. These new cells were able to produce insulin in response to changing glucose levels.Read more
More
Lab Generated, Insulin Producing Cells Prevent Onset of Diabetes
Jan 11,2016
Using Nanoparticles to Combat Arteriosclerosis
In industrialized countries, a particularly high number of people suffer from arteriosclerosis — with fatal consequences: Deposits in the arteries lead to strokes and heart attacks. A team of researchers under the leadership of the University of Bonn has now developed a method for guiding replacement cells to diseased vascular segments using nanoparticles. The scientistsRead more
More
Jan 11,2016
Hepatitis C Peptide Has Auspicious Antiviral Properties
    The rapid acquisition of drug resistance by viruses is a constant threat and an imminent concern of researchers across the globe. Scientists are always on the hunt to develop therapies that affect a broad range of viral invaders, as well as uncover the molecular mechanisms that lead their demise—all while reducing the possibility of developingRead more
More
Hepatitis C Peptide Has Auspicious Antiviral Properties
Jan 08,2016
Researchers Develop Platform to Track Gene Expression Through Generations of Cells
    MIT researchers have developed a microfluidic platform allowing them to trace cells as they divide. Using the platform, the researchers were also able to remove the daughter cells for single-cell analysis, as MIT’s Scott Manalis and his colleagues reported in Nature Communications.     "Existing methods allow for snapshot measurements of single-cell gene expression, which can provideRead more
More
Jan 08,2016
High Mutation Rate of Ebola Could Be Its Achilles Heel
    Researchers at the Texas Biomedical Research Institute completed a study that concluded that the high mutation rate of the Ebola virus may provide the basis for developing effective therapies.     In an online paper (” Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency”), published in the Journal of Virology, Anthony Griffiths, Ph.D., associate scientist,Read more
More
Jan 07,2016
Minor Flu Strains Can Cause Major Health Problems
    A team of scientists has recently discovered that minor variants of flu strains, which are normally ignored by vaccine makers, can be extremely virulent. This theory is far removed from previous studies which considered these minor strains to be relatively harmless.     It's a known fact that the Influenza A virus is marked by a highRead more
More
Jan 07,2016
Breast Cancer Recurrence Associated with Weak T Cell Response
    In the past several years researcher have made a number of significant advances in cancer treatments through advanced detection methods and new drug therapies. However, due to the complex heterogeneity that comprises most tumors, complete eradication of all cancer cells, especially for breast cancer, is still proving to be tough.     Now, scientists from the UniversityRead more
More
Breast Cancer Recurrence Associated with Weak T Cell Response
Jan 06,2016
Role of STING Protein in Development of Colorectal Cancer
    A new study published by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine (Sylvester) reports on a key finding about the immune system's response to tumor development following studies on colorectal cancer. This is the first detailed examination of how the stimulator of interferon genes (STING) signaling pathway,Read more
More
Role of STING Protein in Development of Colorectal Cancer
Jan 06,2016
Scientists Use CRISPR to Treat Duchenne Muscular Dystrophy
    The year 2015 has been a banner one for the field of genome editing. Molecular manipulation tools like the CRISPR/Cas9 system are becoming more refined and utilized to rectify a multitude of diseases in the laboratory, with an ever-watchful eye toward use in clinical trials.       In a landmark study, a research team led byRead more
More
Scientists Use CRISPR to Treat Duchenne Muscular Dystrophy
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->